AU2018210404B2 - ApoC-II mimetic peptides - Google Patents

ApoC-II mimetic peptides Download PDF

Info

Publication number
AU2018210404B2
AU2018210404B2 AU2018210404A AU2018210404A AU2018210404B2 AU 2018210404 B2 AU2018210404 B2 AU 2018210404B2 AU 2018210404 A AU2018210404 A AU 2018210404A AU 2018210404 A AU2018210404 A AU 2018210404A AU 2018210404 B2 AU2018210404 B2 AU 2018210404B2
Authority
AU
Australia
Prior art keywords
apoc
peptide
helix
certain embodiments
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018210404A
Other languages
English (en)
Other versions
AU2018210404A1 (en
Inventor
Madhav N. Devalaraja
Soumitra Shanker Ghosh
Chih-Hung Lo
Alan Thomas REMALEY
Denis O. Sviridov
Anna WOLSKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
US Department of Health and Human Services
Original Assignee
Novo Nordisk AS
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, US Department of Health and Human Services filed Critical Novo Nordisk AS
Publication of AU2018210404A1 publication Critical patent/AU2018210404A1/en
Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, CORVIDIA THERAPEUTICS, INC. reassignment THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES Amend patent request/document other than specification (104) Assignors: CORVIDIA THERAPEUTICS, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMETN OF HEALTH & HUMAN SERVICES
Assigned to NOVO NORDISK A/S, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES reassignment NOVO NORDISK A/S Request for Assignment Assignors: CORVIDIA THERAPEUTICS, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Application granted granted Critical
Publication of AU2018210404B2 publication Critical patent/AU2018210404B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2018210404A 2017-01-19 2018-01-19 ApoC-II mimetic peptides Active AU2018210404B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762448358P 2017-01-19 2017-01-19
US62/448,358 2017-01-19
US201762476535P 2017-03-24 2017-03-24
US201762476531P 2017-03-24 2017-03-24
US62/476,531 2017-03-24
US62/476,535 2017-03-24
PCT/US2018/014532 WO2018136803A1 (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Publications (2)

Publication Number Publication Date
AU2018210404A1 AU2018210404A1 (en) 2019-08-08
AU2018210404B2 true AU2018210404B2 (en) 2022-01-27

Family

ID=62908746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018210404A Active AU2018210404B2 (en) 2017-01-19 2018-01-19 ApoC-II mimetic peptides

Country Status (14)

Country Link
US (2) US11136372B2 (enExample)
EP (1) EP3571216A4 (enExample)
JP (2) JP7353973B2 (enExample)
KR (1) KR102700862B1 (enExample)
CN (1) CN110831957B (enExample)
AU (1) AU2018210404B2 (enExample)
BR (1) BR112019014707A2 (enExample)
CA (1) CA3050106A1 (enExample)
IL (2) IL268093B2 (enExample)
MX (1) MX2019008529A (enExample)
NZ (1) NZ755599A (enExample)
SG (2) SG11201906422VA (enExample)
TW (2) TWI788323B (enExample)
WO (1) WO2018136803A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136803A1 (en) 2017-01-19 2018-07-26 The United States Of America, As Represented By The Secretary Departmetn Of Health & Human Services Apoc-ii mimetic peptides
CN117580857A (zh) * 2021-06-23 2024-02-20 美国政府(由卫生和人类服务部的部长所代表) Apoc-ii短模拟肽及使用方法
WO2023215838A1 (en) * 2022-05-05 2023-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Short apolipoprotein e mimetic peptides and methods of use
EP4565251A1 (en) * 2022-08-07 2025-06-11 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
US20050202532A1 (en) * 2002-05-08 2005-09-15 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US20110033518A1 (en) * 2008-04-15 2011-02-10 Remaley Alan T Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
MXPA04002848A (es) 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
US7220576B2 (en) * 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
CA2512879A1 (en) * 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
US7691860B2 (en) * 2004-02-19 2010-04-06 Banyu Pharmaceutical Co., Ltd. Sulfonamide derivatives
US7569546B2 (en) * 2004-07-16 2009-08-04 Trustees Of Tufts College Apolipoprotein A1 mimetics and uses thereof
AU2006263332B2 (en) * 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
EP2484692A4 (en) 2009-09-30 2013-03-06 Snu R&Db Foundation MIMETIC APOLIPOPROTEIN A-1-PEPTIDES AND THERAPEUTICS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DISEASES RELATED TO HYPERLIPIDEMIA THEREWITH
BR112015010276A2 (pt) 2012-11-06 2019-10-15 Hoffmann La Roche peptídeos miméticos
WO2018136803A1 (en) 2017-01-19 2018-07-26 The United States Of America, As Represented By The Secretary Departmetn Of Health & Human Services Apoc-ii mimetic peptides
EA201991491A1 (ru) 2017-03-24 2019-12-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис Миметические пептиды apoc-ii

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
US20050202532A1 (en) * 2002-05-08 2005-09-15 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US20110033518A1 (en) * 2008-04-15 2011-02-10 Remaley Alan T Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMAR, M, J. ET AL, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (2014-11-13), vol. 352, no. 2, doi:10.1124/jpet.114.220418, ISSN 0022-3565, pages 227 - 235 *
BAGGIO ET. AL., J Clin Invest. 1986;77(2):520-527. *
STORJOHANN, R ET AL, MOLECULAR AND CELL BIOLOGY OF LIPIDS, ELSEVIER, AMSTERDAM, NL, (2000-07-19), vol. 1486, no. 2-3, doi:10.1016/S1388-1981(00)00062-7, ISSN 1388-1981, pages 253 - 264 *

Also Published As

Publication number Publication date
MX2019008529A (es) 2020-02-07
AU2018210404A1 (en) 2019-08-08
SG10201911974UA (en) 2020-02-27
US20200140522A1 (en) 2020-05-07
NZ755599A (en) 2022-12-23
WO2018136803A1 (en) 2018-07-26
IL279831A (en) 2021-03-01
JP7353973B2 (ja) 2023-10-02
TW202130652A (zh) 2021-08-16
IL268093B1 (en) 2024-03-01
TWI788323B (zh) 2023-01-01
IL268093A (en) 2019-09-26
TW201835097A (zh) 2018-10-01
IL268093B2 (en) 2024-07-01
EP3571216A1 (en) 2019-11-27
SG11201906422VA (en) 2019-08-27
BR112019014707A2 (pt) 2020-04-07
EP3571216A4 (en) 2020-11-04
KR102700862B1 (ko) 2024-08-30
US11827690B2 (en) 2023-11-28
CA3050106A1 (en) 2018-07-26
US20210324043A1 (en) 2021-10-21
JP2020511425A (ja) 2020-04-16
WO2018136803A8 (en) 2019-08-01
US11136372B2 (en) 2021-10-05
JP2023116739A (ja) 2023-08-22
CN110831957B (zh) 2024-02-09
KR20190121305A (ko) 2019-10-25
CN110831957A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
US11827690B2 (en) ApoC-II mimetic peptides
CA2954475C (en) Apoe mimetic peptides and higher potency to clear plasma cholesterol
US9815869B2 (en) SP-B and SP-C peptides, synthetic lung surfactants, and use thereof
JP2012518006A (ja) アポリポタンパクａ−ｉ模倣物
JP2019089834A (ja) アポリポタンパク質模倣体及びその使用
JP2007534612A (ja) 高コレステロール血症の治療のためのコレステロール逆輸送メディエータ
US20240309065A1 (en) Short apoc-ii mimetic peptides and methods of use
EA042134B1 (ru) МИМЕТИЧЕСКИЕ ПЕПТИДЫ apoC-II
US20170305981A1 (en) Synthetic peptides
HK1242718A1 (en) Apoe mimetic peptides and higher potency to clear plasma cholesterol

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH

Free format text: FORMER NAME(S): THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMETN OF HEALTH & HUMAN SERVICES ; CORVIDIA THERAPEUTICS, INC.

Owner name: CORVIDIA THERAPEUTICS, INC.

Free format text: FORMER NAME(S): THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMETN OF HEALTH & HUMAN SERVICES ; CORVIDIA THERAPEUTICS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: NOVO NORDISK A/S

Free format text: FORMER APPLICANT(S): CORVIDIA THERAPEUTICS, INC.; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Free format text: FORMER APPLICANT(S): CORVIDIA THERAPEUTICS, INC.; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

FGA Letters patent sealed or granted (standard patent)